- Pharmillenium Consulting
Main menu:
-
- Home Page
- About
- Contact us
-
- News
- Scope of services
- Clinical Laboratory Support
- References
- Sources of information
- Our Clients
news
European Medicines Agency
EMEA
PharmaNews.eu - the dynamic European pharmaceutical news engine.
PharmaNews.eu - the dynamic European pharmaceutical news engine.
- The European Medicines Agency is warning that young children may experience fever after their second dose of the pandemic influenza vaccine Pandemrix. Prescribers and parents should monitor the temperature of the vaccinated child and, if necessary, take measures to lower the fever (e.g. giving an antipyretic such as paracetamol). However, the Agency noted that the second dose increases the immune response against pandemic influenza.
- EMEA makes recommendations to minimise risk of nephrogenic systemic fibrosis with gadolinium-containing contrast agents
The European Medicines Agency (EMEA) has adopted a set of recommendations aimed at minimising the risk of nephrogenic systemic fibrosis (NSF) with gadolinium-containing contrast agents in patients at risk of developing the condition. Gadolinium-containing contrast agents are used in patients undergoing magnetic resonance imaging (MRI) or magnetic resonance angiography (MRA) scans. - European Medicines Agency 2009 mid-year report shows it is still on target, despite influenza pandemic activities
The European Medicines Agency is performing on target despite the increase of activities relating to the influenza pandemic. This was the message given by the Agency's Executive Director, Thomas Lönngren, when he presented the mid-year report to the Management Board at its meeting on 1 October 2009. - European Medicines Agency implements internal reorganisation
The European Medicines Agency has begun implementing a series of changes to its internal organisation aimed at improving the functioning of the Agency and the way in which it delivers its core tasks. The changes will be introduced gradually from September to December 2009. - European Medicines Agency recommends authorisation of additional vaccine for influenza pandemic (H1N1) 2009
The European Medicines Agency has recommended to the European Commission that an additional vaccine against influenza A(H1N1) ('swine flu'), Celvapan from Baxter, be granted a marketing authorisation. Adoption of an authorisation decision by the European Commission is expected shortly. This recommendation follows the authorisation of Focetria, from Novartis, and Pandemrix, from GlaxoSmithKline, by the European Commission on 29 September 2009.